EGFR exon in lung cancer: Survival predictors?

I. Ladeira, A. Antunes, C. Ribeiro, A. Barroso, S. Conde, B. Parente (Vila Nova de Gaia, Portugal)

Source: Annual Congress 2012 - Prognosis of lung cancer
Session: Prognosis of lung cancer
Session type: Thematic Poster Session
Number: 4169
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Ladeira, A. Antunes, C. Ribeiro, A. Barroso, S. Conde, B. Parente (Vila Nova de Gaia, Portugal). EGFR exon in lung cancer: Survival predictors?. Eur Respir J 2012; 40: Suppl. 56, 4169

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Model for predicting EGFR mutation status in lung cancer
Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019
Year: 2019



Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009

Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Source: Eur Respir J 2012; 40: 177-184
Year: 2012



Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011


Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015


Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012


Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011



Biological analysis of the single codon deletion in Exon 19 of EGF receptor in non-small cell lung cancer responsive to gefitinib
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009


Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010

Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010

Is gender a prognostic factor in long term survival non-small cell lung cancer?
Source: Eur Respir J 2002; 20: Suppl. 38, 185s
Year: 2002

A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005

A polymorphism, which exists intronic lesion of SLC5A10, affects DRG2 expression and survival outcome of early-stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015


Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015

Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017


EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014

Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010